The Journal of the Association of Physicians of India

Real-World Experiences Using Semaglutide at a Hospital in Jharkhand

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Semaglutide has shown effectiveness in improving glycemic control and reducing cardiovascular risk in patients with type 2 diabetes mellitus.

  • Evidence of semaglutide's impact on glycemic control is derived from clinical settings.
  • The drug is associated with reductions in body weight among patients with type 2 diabetes.
  • Semaglutide may also influence various metabolic parameters in this population.
  • Real-world evidence specifically from Indian populations is currently limited.

Simplified

Related papers

Jan '25
Real-world study of daily oral semaglutide treatment in people aged 65 and older with type 2 diabetes
top 5% journal
cited by 7 papers
journal article
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 10 papers
observational study
Feb '25
Long-term effects of daily oral semaglutide added to or replacing other treatments in adults with type 2 diabetes over 12 months
top 20% journal
cited by 2 papers
journal article
Aug '24
Weekly Semaglutide Injection Use in People with Type 2 Diabetes in Spain
top 10% journal
cited by 7 papers
multicenter study
Mar '25
Daily oral semaglutide's safety and effectiveness in people with type 2 diabetes switching from sulfonylurea medications
top 5% journal
cited by 2 papers
multicenter study
Apr '26
Blood Sugar Control, Heart and Kidney Health Signs, and Safety of Polyethylene Glycol Loxenatide Compared to Semaglutide in Chinese Patients with Type 2 Diabetes
top 10% journal
multicenter study
Apr '26
Use of semaglutide in people with type 2 diabetes and severe kidney failure in real-life settings
top 10% journal
multicenter study
Oct '24
Real-life study of injected semaglutide in Spanish patients with type 2 diabetes who have used similar treatments before
top 20% journal
cited by 3 papers
multicenter study
Aug '24
Semaglutide doses of 0.5 mg and 1 mg in type 2 diabetes patients and factors linked to treatment response
top 10% journal
cited by 8 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief